The inhibition of the protein KRAB box and zinc finger, C2H2 type domain containing through the application of these chemicals involves a range of both direct and indirect mechanisms, highlighting the complexity of protein functionality and regulation. Direct inhibitors such as Staurosporine, Bisindolylmaleimide I, and H-89 target potential kinase-like domains within the protein. Staurosporine, a well-known kinase inhibitor, binds to these domains and interferes with phosphorylation-related functions, a key aspect of the protein's activity. Bisindolylmaleimide I, typically associated with inhibiting protein kinase C, similarly disrupts kinase activities within the protein by targeting kinase-like domains. H-89, which inhibits protein kinase A, prevents phosphorylation activities within KRAB box and zinc finger, C2H2 type domain containing by binding to these kinase domains. Indirect inhibitors such as LY294002, Rapamycin, U0126, Wortmannin, SB203580, SP600125, PD98059, Genistein, and Lavendustin A operate through modulation of various signaling pathways that are crucial for the protein's functionality. LY294002 disrupts the PI3K/AKT pathway, a critical signaling pathway that may interact with or regulate KRAB box and zinc finger, C2H2 type domain containing, thereby indirectly affecting its function. Rapamycin targets mTOR, a major regulator of cell growth and proliferation, influencing downstream kinases and signaling pathways associated with the protein. U0126 affects the MAPK pathway, potentially altering the interactions or regulation of the protein within cellular signaling networks. Wortmannin, by inhibiting PI3K, disrupts its interaction with the PI3K/AKT pathway, which could be crucial for the functionality of KRAB box and zinc finger, C2H2 type domain containing.
SB203580 and SP600125 target p38 MAP kinase and JNK, respectively, indicating the role of these kinases in downstream signaling pathways that regulate the protein. PD98059, by inhibiting MEK, impacts the ERK pathway, potentially affecting pathways that interact with KRAB box and zinc finger, C2H2 type domain containing. Genistein and Lavendustin A, both tyrosine kinase inhibitors, suggest the involvement of tyrosine kinase-related activities in the protein's functionality. By inhibiting these kinases, they potentially affect pathways related to the protein's activity. In summary, the diverse range of chemical inhibitors, both direct and indirect, highlights the intricate network of signaling pathways and protein interactions that regulate the functionality of KRAB box and zinc finger, C2H2 type domain containing. These inhibitors, by targeting specific domains within the protein or by modulating crucial signaling pathways, provide insight into the complex regulatory mechanisms that govern the protein's activity within the cellular environment.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits KRAB box and zinc finger, C2H2 type domain containing by binding to kinase-like domains, interfering with functional activities related to phosphorylation. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I inhibits KRAB box and zinc finger, C2H2 type domain containing by targeting kinase-like domains, disrupting kinase activities. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 indirectly inhibits KRAB box and zinc finger, C2H2 type domain containing by disrupting PI3K/AKT pathway interactions, affecting downstream signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin indirectly inhibits KRAB box and zinc finger, C2H2 type domain containing by inhibiting mTOR, affecting downstream kinase signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 indirectly inhibits KRAB box and zinc finger, C2H2 type domain containing by affecting the MAPK pathway, altering interactions with or regulation of the protein. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin indirectly inhibits KRAB box and zinc finger, C2H2 type domain containing by targeting PI3K, disrupting its interaction with the PI3K/AKT pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 indirectly inhibits KRAB box and zinc finger, C2H2 type domain containing by targeting p38 MAP kinase, affecting downstream signaling pathways that regulate the protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 indirectly inhibits KRAB box and zinc finger, C2H2 type domain containing by inhibiting JNK, affecting downstream targets and signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 indirectly inhibits KRAB box and zinc finger, C2H2 type domain containing by blocking MEK activation, affecting downstream ERK pathways that interact with the protein. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein indirectly inhibits KRAB box and zinc finger, C2H2 type domain containing by interfering with tyrosine kinase-related activities, potentially affecting protein functionality. |